(Total Views: 70)
Posted On: 10/20/2023 2:15:47 PM
Post# of 107168
$MRK News Article - KEYTRUDA (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by 28% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC) https://marketwirenews.com/news-releases/keyt...61587.html
(0)
(0)
My Twitter: WhyteStocks
